Search
ADC Therapeutics SA
ADCTAdd to Watchlist
3.435USD
-0.045-1.29%
Market hours （ET）Quotes delayed by 15 min
436.82MMarket Cap
LossP/E TTM
More Details of ADC Therapeutics SA Company
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
ADC Therapeutics SA Info
Ticker SymbolADCT
Company nameADC Therapeutics SA
IPO dateMay 15, 2020
CEOMallik (Ameet)
Number of employees263
Security typeOrdinary Share
Fiscal year-endMay 15
AddressBiopole
CityEPALINGES
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountrySwitzerland
Postal code1066
Phone41216530200
Websitehttps://adctherapeutics.com/
Ticker SymbolADCT
IPO dateMay 15, 2020
CEOMallik (Ameet)
Company Executives of ADC Therapeutics SA
Name
Name/Position
Position
Shareholding
Change
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
2.35M
+10.02%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
--
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
943.88K
+8.69%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
695.69K
+14.14%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
581.57K
+1.47%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.15K
-0.19%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Independent Director
Non-Executive Independent Director
134.98K
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
99.40K
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Non-Executive Independent Director
Non-Executive Independent Director
63.01K
+12.30%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Director
Director
40.00K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Ameet Mallik
Mr. Ameet Mallik
Chief Executive Officer, Director
Chief Executive Officer, Director
2.35M
+10.02%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.58M
--
Mr. Mohamed Zaki, M.D., Ph.D.
Mr. Mohamed Zaki, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
943.88K
+8.69%
Mr. Jose (Pepe) Carmona
Mr. Jose (Pepe) Carmona
Chief Financial Officer
Chief Financial Officer
695.69K
+14.14%
Mr. Peter J. Graham
Mr. Peter J. Graham
Chief Legal and Compliance Officer and Secretary
Chief Legal and Compliance Officer and Secretary
581.57K
+1.47%
Dr. Peter Hug, Ph.D.
Dr. Peter Hug, Ph.D.
Non-Executive Vice Chairman of the Board, Lead Independent Director
Non-Executive Vice Chairman of the Board, Lead Independent Director
180.15K
-0.19%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
By BusinessUSD
Name
Revenue
Proportion
Product
73.55M
90.41%
License revenue
5.00M
6.15%
Royalties
2.81M
3.45%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Product
73.55M
90.41%
License revenue
5.00M
6.15%
Royalties
2.81M
3.45%
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Redmile Group, LLC
9.91%
TCG Crossover Management, LLC
8.96%
HPWH TH AG
6.82%
Prosight Capital
6.67%
OrbiMed Advisors, LLC
4.58%
Other
63.07%
Shareholders
Shareholders
Proportion
Redmile Group, LLC
9.91%
TCG Crossover Management, LLC
8.96%
HPWH TH AG
6.82%
Prosight Capital
6.67%
OrbiMed Advisors, LLC
4.58%
Other
63.07%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
21.16%
Investment Advisor
18.99%
Hedge Fund
15.93%
Corporation
6.82%
Individual Investor
6.43%
Research Firm
5.02%
Private Equity
4.58%
Bank and Trust
0.71%
Pension Fund
0.12%
Other
20.25%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
205
87.78M
69.09%
-1.77M
2025Q4
191
72.94M
63.83%
-1.48K
2025Q3
203
72.94M
76.75%
+266.41K
2025Q2
196
72.67M
64.60%
+13.50M
2025Q1
198
59.17M
80.56%
-20.65M
2024Q4
201
60.84M
78.41%
+1.63M
2024Q3
204
59.22M
80.70%
+2.20M
2024Q2
196
56.12M
64.88%
+18.35M
2024Q1
159
35.17M
75.47%
-27.30M
2023Q4
158
34.44M
76.49%
-6.23M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Redmile Group, LLC
15.67M
12.33%
--
--
Dec 31, 2025
TCG Crossover Management, LLC
11.39M
8.97%
--
--
Dec 31, 2025
HPWH TH AG
8.67M
6.82%
-1.12M
-11.42%
May 15, 2025
Prosight Capital
8.48M
6.67%
+1.01M
+13.45%
Dec 31, 2025
OrbiMed Advisors, LLC
5.82M
4.58%
-84.50K
-1.43%
Dec 31, 2025
Nantahala Capital Management, LLC
5.48M
4.31%
+3.21M
+141.60%
Dec 31, 2025
Point72 Asset Management, L.P.
5.01M
3.95%
-3.12M
-38.36%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
4.85M
3.82%
+868.36K
+21.78%
Dec 31, 2025
Oaktree Capital Management, L.P.
4.41M
3.47%
+392.78K
+9.78%
Sep 30, 2025
Eventide Asset Management, LLC
3.36M
2.65%
+3.36M
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.06%
SPDR S&P International Small Cap ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Growth ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Fidelity Enhanced Small Cap ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.06%
SPDR S&P International Small Cap ETF
Proportion0.04%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Growth ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Fidelity Enhanced Small Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
